Quality and effectiveness of diabetes care for a group of patients in Colombia

Machado‐Alba, Jorge Enrique; Moncada-Escobar, Juan C.; Gaviria, Henry

doi:10.1590/s1020-49892009001200008

Cited by 20 publications

(30 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the DDD was not modified across follow‐up despite not reaching therapeutic goals, being even lower than recommended in some of the groups. Even so, the proportion of patients with metabolic control was similar to previous reports (30%–50%) …”

Section: Discussionsupporting

confidence: 90%

“…Colombia is one of five Latin American countries with the highest number of cases of diabetes mellitus. Previous studies indicate that people with T2DM of Colombia has on average 62.4 years, mainly women (55.0%), with low education level, with overweight (44%) and obesity (30.2%) and is specially treated with metformin (71.5%) and insulin (28.5%) . The Colombian healthcare system (SGSSS) is accessible to all of the population and includes full access to human and analogue insulin.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the impact of human vs analogue insulins on glycosylated haemoglobin in a population with diabetes mellitus

Machado‐Alba

Medina-Morales

2016

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Comparison of the impact of human vs analogue insulins on glycosylated haemoglobin in a population with diabetes mellitus

Machado‐Alba

Medina-Morales

2016

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…In a retrospective study to assess quality and effectiveness of diabetes care for a group of patients in Colombia it was shown that only 6.9% of patients had achieved the goals recommended for control of glucose, lipids and blood pressure. 4 However such surveys are lacking in India and we do not have data regarding achievement of ADA recommendations in Indian setting.…”

Section: Introductionmentioning

confidence: 96%

“…4 In recently published data from a nationwide survey in United States during the period 2007e2010 out of a cohort of 4296 adults 20 years with diabetes, 52.5% of patient had HbA1c < 7%, 51% had BP < 130/80 mm Hg, 56.2% achieved LDL < 100 mg/dl and 18.8% achieved all three parameters. 10 …”

mentioning

confidence: 99%

The ABC of diabetes. How many patients are able to achieve the goal laid down by American Diabetes Association?

Menon

Ahluwalia

2015

Medical Journal Armed Forces India

View full text Add to dashboard Cite

TargetOptimum care a b s t r a c t were estimated at baseline and prevalence of those at target (HbA1c <7%, BP < 130/ 80 mm Hg, LDL < 100 mg/dl) was documented and repeated at three and six months to monitor improvement in the number of patients at target and trend in improvement of individual parameters. Results:The percentage of patients at target at baseline and six months for HbA1c was (45% vs. 55% p ¼ 0.101), BP < 130/80 mm Hg (27% vs. 25%) and LDL <100 mg/dl (37% vs. 40% p ¼ 0.386). All three parameters were at target in one patient and three patients at six months period. Mean values at baseline and six months of HbA1c 7.46% (95% CI 7.17e7.75) vs 7.21% (95% CI 6.9e7.52), Systolic BP 138 mm Hg (95% CI 135e141), Diastolic BP 86 mm Hg (95% CI 84 e86) and LDL 114 mg/dl (95%CI 107e121) vs. 110 mg/dl (95%CI 105e116) did not show significant improvement (p for trend).Conclusion: Standards of care for HbA1c, blood pressure and LDL remains to be achieved in majority of the diabetic patients.

show abstract

“…El patrón de prescripción de las sulfonilureas dentro del arsenal terapéutico antidiabético se reporta con porcentajes variables: 26,7 y 56 % en Estados Unidos, 40% en Argentina, 58,2 y 64,9% en Colombia, subrayando que la sulfonilurea evaluada en Argentina y Colombia fue exclusivamente la glibenclamida [5][6][7][8][9] .…”

Section: Introductionunclassified

Evaluación de la prescripción de glibenclamida en diabéticos tipo 2

Castro¹,

Estrada

Goez

2017

revsal

View full text Add to dashboard Cite

RESUMENIntroducción: Las sulfonilureas permanecen junto con la metformina como el tratamiento farmacológico más usado para los pacientes diabéticos tipo 2, y continúan siendo los antidiabéticos más prescritos en algunas regiones del mundo. Objetivo: Evaluar la prescripción de glibenclamida en aspectos relacionados a contraindicaciones, dosificación, y prevención de efectos adversos, en el tratamiento de los pacientes diabéticos tipo 2 que acuden a una institución de salud de baja complejidad en Cartagena de Indias, Colombia. Metodología: Estudio descriptivo con enfoque desde la fármaco-epidemiología dirigido específicamente al campo de los estudios de utilización de medicamentos, basado en los datos recogidos mediante revisión de historias clínicas de 331 pacientes diabéticos tipo 2, mayores de 18 años en un centro de atención primaria en salud de la ciudad de Cartagena de Indias entre los años 2013 y 2014. Se estudiaron variables demográficas, clínicas y paraclínicas, el esquema terapéutico y la calidad de la prescripción. La información se analizó usando estadística descriptiva. Resultados: 57 % (189) de los pacientes utilizaron glibenclamida siendo un 59.3 % (153) prescrito de manera inadecuada, 45.5% (86) tenían alguna contraindicación para el empleo del medicamento. En 1 % de los pacientes de la muestra se prescribió sobrepasando el rango de dosis terapéutica Conclusiones: La calidad de la prescripción de la glibenclamida fue inadecuada en una proporción importante de pacientes, se hace necesario implementar estrategias educacionales que capaciten al personal médico para una correcta utilización de los fármacos antidiabéticos. La glibenclamida comparada con otras sulfonilureas de segunda generación nos brinda más desventajas que ventajas.Palabras Clave: Diabetes Mellitus Tipo 2, glibenclamida, contraindicaciones, tasa de filtración glomerular, prescripciones de medicamentos, farmacoepidemiología. ABSTRACTIntroduction: Sulfonylureas remain with metformin as the most used drug treatment for type 2 diabetic patients and remain the most prescribed anti-diabetic in some regions of the world. Target: Evaluate prescribing glyburide in aspects related to contraindications, dosage, and prevention of adverse effects, in the treatment of type 2 diabetic patients attending a health institution low complexity in Cartagena de Indias, Colombia. Methodology: Descriptive study with approach from the pharmaco-epidemiology specifically directed to the field of studies of drug use, based on the data collected through review of medical records of 331 type 2 diabetic patients over 18 years in a primary

show abstract

Quality and effectiveness of diabetes care for a group of patients in Colombia

Abstract: Despite high testing rates, metabolic control was not effective. Low rates of medication adjustment among patients with measures outside target ranges suggest the need for changes in routine diabetes care to ensure therapeutic regimens are adjusted appropriately.

Cited by 20 publications

References 17 publications

Comparison of the impact of human vs analogue insulins on glycosylated haemoglobin in a population with diabetes mellitus

Comparison of the impact of human vs analogue insulins on glycosylated haemoglobin in a population with diabetes mellitus

The ABC of diabetes. How many patients are able to achieve the goal laid down by American Diabetes Association?

Evaluación de la prescripción de glibenclamida en diabéticos tipo 2

Contact Info

Product

Resources

About